Viswanath Abhishek, Drakou Eftychia E, Lajeunesse-Trempe Fannie, Grossman Ashley B, Dimitriadis Georgios K
Faculty of Life Sciences and Medicine, School of Life Course Sciences, King's College London, London, UK.
Department of Clinical Oncology, Guy's Cancer Centre - Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London, UK.
Best Pract Res Clin Endocrinol Metab. 2025 Mar;39(2):101966. doi: 10.1016/j.beem.2024.101966. Epub 2024 Dec 27.
Parathyroid carcinoma (PC) is a rare malignancy, comprising 1 % of all cases of primary hyperparathyroidism (PHPT). This narrative review explores recent advances in PC management, with a focus on molecular insights, diagnostic advancements, surgical innovations, and emerging targeted therapies. Manuscripts published between 2023 and 2024 were obtained from PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL). The review highlights advances in biochemical markers, such as circulating tumour cells (CTCs), and imaging modalities such as F-FDG PET/CT and 4D-CT, which are improving diagnostic accuracy. Surgical resection remains central to localised and metastatic disease management. For patients with widespread metastatic or unresectable disease, newer targeted approaches such as tyrosine kinase inhibitors (TKIs), temozolomide, and immune checkpoint inhibitors (ICIs) may offer clinical benefit to specific patient cohorts. This review identifies future research areas to improve outcomes and recommends that patients with advanced PC continue to be managed in centres of excellence.
甲状旁腺癌（PC）是一种罕见的恶性肿瘤，占所有原发性甲状旁腺功能亢进症（PHPT）病例的1%。本叙述性综述探讨了PC治疗的最新进展，重点关注分子见解、诊断进展、手术创新和新兴的靶向治疗。从PubMed、EMBASE和Cochrane对照试验中央注册库（CENTRAL）获取了2023年至2024年发表的手稿。该综述强调了生化标志物（如循环肿瘤细胞（CTC））和成像方式（如F-FDG PET/CT和4D-CT）的进展，这些正在提高诊断准确性。手术切除仍然是局限性和转移性疾病治疗的核心。对于广泛转移或无法切除的疾病患者，酪氨酸激酶抑制剂（TKIs）、替莫唑胺和免疫检查点抑制剂（ICIs）等新的靶向方法可能会给特定患者群体带来临床益处。本综述确定了未来改善治疗结果的研究领域，并建议晚期PC患者继续在卓越中心接受治疗。
